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ABSTRACT 
Background 
The risk of complications from T2DM is high. Complications reduce quality of life and 
place a large burden on our health system and economy. Achieving targets in our 
diabetic patients significantly reduces the morbidity and mortality of the disease. This 
study aims to assess whether patients at the Helen Joseph Academic Hospital Diabetic 
Clinic are meeting the 2012 SEMDSA targets for diabetes with the current hospital 
treatment protocols.   
 
Methods  
A Retrospective Clinical Audit was carried out at the Helen Joseph Hospital Diabetic 
Clinic. The files of 321 patients with T2DM for a duration of longer than five years and 
who were on insulin were reviewed. The following information was assessed: Glycated 
haemoglobin (HbA1c), Blood pressure, abdominal circumference and lipograms. 
 
Results 
The study population of 321 patients compromised majority black (44.6%) and 
coloured (34%) patients. The mean age amongst these patients was 59.4 years. This 
sample was predominantly female (62.3%). A large proportion of patients had 
concomitant Hypertension (89.1%) and dyslipidaemia (82.2%); with 91.2% fulfilling 
criteria for the diagnosis of metabolic syndrome. The majority of patients 56.3% did not 
exercise. A small amount partook in recreational activities that increase cardiovascular 
risk (smoking 12.5% and alcohol use 10.6%). Target HbA1c used for the purpose of 
this study was 7% or lower. The mean HbA1c in this study population was 9.5% (range 
3.9 – 16.9%). Only 15.3% achieved the 7% target. The number of patients who 
achieved the target Blood Pressure of <140/90 was 72 (25%) (95% CI 20.2-30.5). LDL 
target was achieved in 22.6% and abdominal circumference 11%. 
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Conclusions 
Despite adequate protocols and access to tertiary medical care, only a very small 
percentage of patients at the diabetic clinic are achieving proposed targets. Other 
audits have revealed a range of reasons for poor control in their patients. More 
comprehensive analysis is required to assess the reasons in this clinic if we are to 
address the problem with the urgency it requires. Ultimately, the goal is to offer the 
best treatment and quality of life to our ever increasing diabetic population. 
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1. LITERATURE REVIEW 
The global burden of non-communicable diseases (NCD) is rapidly escalating.(1) 
More than 63% of annual global deaths (approximately 36 million people) can be 
attributed to NCD’s with the large majority (86%) occurring in low to middle income 
countries.(2) The impact on society, the economy and the health sector is immense 
and could be crippling if not attended to with utmost urgency.(2–6)   The World Health 
Organisation (WHO) and the United Nations (UN) have listed the following four 
NCD’s as areas for intervention over the next few decades: cardiovascular diseases, 
cancers, chronic respiratory diseases and Diabetes Mellitus (DM).(1, 2, 5) The main 
focus of this work is DM. 
 
1.1 A Brief History of Diabetes 
DM is first described within the Ebers Papyrus, a document of ancient Egyptian 
medicine written in approximately 1500B.C.(7) Here it is described as a disease of 
“too great emptying of the urine”. The first complete description of DM is credited to 
Aretaeus of Cappadocia who coined the term “Diabetes” in the 1st century A.D.(7) 
Ancient Indian physicians also describe a disease as known as “Madhumeha” (sweet 
urine) in their 5th century texts and document cases of patients with excessive 
urination, excessive thirst and emaciation occurring more commonly in rich people 
who consumed large amounts of rice, cereals and sweets.(8)  
 
The various clinical features and complications of DM were described by various 
physicians over the following centuries and during this time was widely thought to be 
a disease that originated in the kidneys.(8) Swiss physician Paracelsus in the 16th 
century A.D. was the first to describe the disease as a process originating outside the 
kidneys.(9) The term Mellitus was coined by John Rollo in 1798 in order to distinguish 
between polyuria with glycosuria and polyuria of other origins.(7)  
 
During the late 18th and early 19th centuries, patients with DM were shown to have 
glucose in the blood and urine and tests to identify these abnormalities were 
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refined.(8) In the late 19th century the islets of Langerhans were identified and the 
causal relationship between lesions in the pancreas and the development of DM was 
described.(8,9) Large strides were made in the 20th century, with the identification of 
insulin and its use in treatment; development of diagnostic and monitoring tools and a 
multitude of oral and injectable drugs for treatment.(7–9) 
 
1.2 Definition and Classification 
Prior to the 1970’s the nomenclature and diagnostic criteria for DM varied. In 1979 
the WHO and the American National Diabetes Data Group (NDDG) published 
diagnostic criteria and classification systems for DM.(3) In 1995 an international expert 
committee was put together to revise the classification systems and diagnostic 
criteria defined in 1979.(10) The current definition of DM is “a metabolic disorder of 
multiple aetiology characterised by chronic hyperglycaemia and disturbances of 
carbohydrate, fat and protein metabolism resulting from defects in insulin secretion, 
insulin action, or both”.(11–13)  
 
The different types of DM are classified according to aetiology.(10) They are: 
1.2.1 Type 1 Diabetes Mellitus (T1DM) 
Immune Mediated 
T1DM constitutes 5-10% of diabetes cases.(14) It occurs as a results of pancreatic β -
cell destruction through cell-mediated autoimmune processes. (10,15) Autoantibodies to 
insulin, Glutamic acid decarboxylase (GAD), islet cells and tyrosine phosphates can 
be demonstrated in 85-90% of patients.(16) A combination of genetic predisposition 
and environmental factors (such as autoimmune activation of antibodies by viral 
infections) are responsible for β-cell destruction. β-cell destruction rate is variable 
and can be slowly or rapidly progressive.(14, 1) This type of DM is common in children. 
When it occurs in adults a slow onset of insulin dependency related to the presence 
of insulin cell antibodies is noted. Here it is called latent autoimmune diabetes in 
adults (LADA).(18,19) The hallmark of this disease is little or no insulin secretion with 
low to undetectable c-peptide level and a predisposition to ketoacidosis.(10, 16, 19) 
3 
 
Idiopathic 
This form predominantly affects people of African and Asian descent, is strongly 
inherited and has no known aetiology or demonstrable autoantibodies. Individuals 
present with varying degrees of insulin deficiency interspersed with episodes of 
ketoacidosis.(16) 
 
1.2.2 Type 2 Diabetes Mellitus (T2DM) 
(This will be the focus of further sections in this document) 
This type accounts for 90-95% of cases worldwide.(16) Though exact aetiology is 
unknown, a strong familial (most likely genetic) link has been demonstrated.(11, 15) 
Factors that increase the risk of developing T2DM have been identified. These 
include: obesity, lack of physical activity, increasing age and a history of gestational 
DM amongst others.(16)  The disease in these patients is attributable to disorders of 
insulin action (insulin resistance) and secretory defects causing relative insulin 
deficiency.(10,11,18)The onset of T2DM is, in most cases, insidious and asymptomatic 
due to low levels of hyperglycaemia and many patients remain undiagnosed for long 
periods.(11,21) Nevertheless, the risk of developing complications during this period 
remain high.(16) 
 
1.2.3 Gestational DM 
This is defined as any degree of glucose intolerance which begins in or is first 
recognised during pregnancy and which does not fit criteria for overt diabetes. This 
form of glucose intolerance usually resolves after delivery. (11,22) 
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1.2.4 Other Specific Types of DM 
These are relatively uncommon forms of DM in which a specific defect or disease 
process can be identified as the cause.(11) These include DM associated with other 
diseases or drugs and specific genetically defined types.(18) 
Table 1.1: Other Specific Types of DM (11,18,22) 
Genetic defects of beta-cell function  
Chromosome 20, HNF4a (*MODY1)  
Chromosome 7, glucokinase (*MODY2)  
Chromosome 12, HNF1a (*MODY3)  
Chromosome 13, IPF-1 (*MODY4)  
Mitochondrial DNA 3243 mutation  
Others 
Genetic defects in insulin action  
Type A insulin resistance  
Leprechaunism  
Rabson-Mendenhall syndrome  
Lipoatrophic diabetes  
Others 
 
Diseases of the exocrine pancreas  
Fibrocalculous pancreatopathy  
Pancreatitis  
Trauma / pancreatectomy  
Neoplasia Cystic fibrosis  
Haemochromatosis  
Others 
 
Endocrinopathies  
Cushing's syndrome  
Acromegaly  
Phaeochromocytoma  
Glucagonoma  
Hyperthyroidism  
Somatostatinoma  
Others  
Drug- or chemical-induced  
Nicotinic acid  
Glucocorticoids  
Thyroid hormone  
Alpha-adrenergic agonists  
Beta-adrenergic agonists  
Thiazides  
Dilantin 
Other genetic syndromes 
Down's syndrome  
Friedreich's ataxia  
Huntington's chorea  
Klinefelter's syndrome  
Lawrence-Moon-Biedel syndrome  
Myotonic dystrophy  
Porphyria  
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Pentamidine  
Vacor  
Interferon-alpha therapy  
Others 
 
Prader-Willi syndrome  
Turner's syndrome  
Wolfram's syndrome 
Others  
Infections  
Congenital rubella 
Cytomegalovirus  
Others  
 
Uncommon forms of immune-mediated 
diabetes  
Insulin autoimmune syndrome (antibodies to  
insulin)  
Anti-insulin receptor antibodies "Stiff Man"  
syndrome  
Others  
 
*MODY – Mature onset diabetes of the young 
 
1.3 Epidemiology and Socioeconomic Impact 
In 2015 the International Diabetes Federation (IDF), estimated that 415 million 
people worldwide or 8.8% of people aged 20-79 years are living with DM and this 
number is estimated to rise to 642 million people by 2040.(21) Approximately 75% of 
these people live in low to middle income countries.(21) The scarcity of nationwide 
data for the majority of African countries makes the estimates for Africa uncertain. 
Nevertheless, from available data the IDF estimates that the prevalence of diabetes 
in Africa was 3.2% in 2015 (between 9.5 and 29.5 million people). In addition, an 
estimated 66.7% of these people are undiagnosed, the largest proportion in any IDF 
region.(21) The IDF estimated prevalence of diabetes in the South African population 
is 7% (1.2-4.6 million adults aged 20-79).(21) Of the 2.3 million South Africans with 
diabetes, 61.1% (1.4 million) were undiagnosed. The 2010 estimate for South Africa 
was 4.5%.(23) That is a greater than 60% increase in just 5 years.  
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This rapid increase in the number of people with DM is a worldwide phenomenon. 
This is concerning when one considers the impact that DM has on every level of 
society, from the individual suffering with the disease, family members, nationwide 
health systems and economics and the world at large.(3, 20)  Individuals suffering from 
DM have been noted to spend more on health care compared to their 
contemporaries without DM and health systems require increased budgets to 
facilitate care of the disease and its complications.(24,25) The IDF estimates that 
11.6% of global health expenditure is spent on diabetes, three quarters of which 
occurs in middle and low income countries.(21) In 2015, the cost per person annum for 
people with DM in South Africa was R 26 743.69.(21) 
 
 Additionally, families, employees and economy suffer because of loss of 
productivity/income that occur as a result of disabilities caused by DM complications 
and deaths.(26) DM is one of the leading causes of death worldwide and is projected 
to be the 7th leading cause of death in 2030.(21) The IDF reported 5 million deaths 
from DM worldwide in 2015. In 2016, DM was reported as the cause of death for 5% 
of cases in South Africa.(27) 
 
The reasons for the global increase in DM are multiple. These include: 
1.3.1 Increasing age of the world’s population 
The incidence of DM increases with age.(16) As the number of people in older age 
groups increase, so too does the prevalence of DM increase; and the proportion of 
older individuals worldwide has increased substantially in last few decades.(28) 
According to the 2015 UN World Population Prospects report, 1 in every 8 individuals 
(904 million people) is 60 years old or older. With the expected increase of 56% in 
the next 45 years. This means, that by 2050 there will be 1.4 billion people aged 60 
years and older.(28)  
 
Moreover, the rate of increase in population ageing over the next few decades in 
developing countries is expected to be much faster than what has previously 
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occurred in developed countries, forcing them to adapt to these changes much more 
rapidly and likely with lower national incomes than the developed countries.(28) 
 
1.3.2 Urbanisation 
More than 50% of the world’s population currently resides in cities.(29) With the 
change from rural to urban living comes the problem of unbalanced and often 
unhealthy diet, sedentary lifestyle, increase in obesity rates and easier access to 
smoking, alcohol and other drugs. These increase the risks and thus the rates of all 
NCD.(29–31) 
 
1.3.3 Overweight and Obesity 
The WHO defines overweight as Body Mass Index (BMI) >25-29.9kg/m2 and obese 
as BMI >30kg/m2.(1) The prevalence of both overweight and obese individuals is 
rising globally. Worldwide prevalence of overweight adults is 39%, while prevalence 
rates for obesity in males and females are 11% and 15% respectively.  Obese 
individuals can be divided into two groups: the metabolically healthy obese (MBO) 
and the insulin resistant obese (IRO).(32) Evidence for the increased risk of NCD and 
mortality in the IRO is overwhelming.(33,34) In the MBO individual, there is conflicting 
evidence with regard to risk of NCD and mortality.(34) Most interventional programmes 
do not distinguish between the two types. As there is some evidence that the 
individual with MBO is also at higher risk for cardiovascular disease and 
complications, it may be sensible to continue to encourage weight loss in all 
individuals. In keeping with this notion, the WHO recommends that target individual 
BMI be 18.5-24.9kg/m2 and median BMI for adult populations be 21-23kg/m2.(1) 
 
1.3.4 The Metabolic Syndrome 
The Metabolic Syndrome refers to a cluster of interrelated risk factors that confer an 
increased risk of CVD and DM.(35) CVD is doubled and the risk of DM is increased 5-
fold.(36)  Many definitions and diagnostic criteria for the Metabolic Syndrome exist.(36) 
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The harmonised criteria (which is the most commonly used internationally) are as 
follows:(11,18,35,36)  
 
Table 1.2: The Harmonised Criteria for the clinical diagnosis of the Metabolic Syndrome 
*In Sub-Saharan Africa the IDF/Europid definition for elevated waist circumference is used. 
**HDL – high density lipoprotein  
***Drug treatment for elevated triglyceride, blood pressure or glucose or for reduced HDL 
cholesterol is an alternate indicator 
 
Elevated Waist Circumference Population and country specific 
definitions 
*Sub-Saharan Africa: 
≥ 94 cm in men 
≥ 80 cm in women 
Elevated triglycerides ≥ 1.7 mmol/L 
 
Reduced HDL cholesterol ** < 1.0 mmol/L in men 
< 1.3 mmol/L in women 
Elevated Blood Pressure (BP) Systolic ≥ 130 mm Hg 
Diastolic ≥ 85 mm Hg 
Elevated Blood sugar ≥ 5.6 mmol/L 
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1.4 Diagnosis and Screening for T2DM 
The WHO, ADA and Society for Endocrinology Metabolism Diabetes of South Africa 
(SEMDSA) give the following recommendations for diagnosing diabetes.(11, 18, 22, 37) 
Table 1.3: Criteria for diagnosis of DM 
Fasting* Plasma Glucose (FPG) >7.0 mmol/l 
2hour Plasma Glucose (2h PG) in an OGTT** > 11.1 mmol/l 
Glycated Haemoglobin (HbA1c) >6.5% 
Random Plasma Glucose (RPG) >11.1 mmol/l in presence of classic 
symptoms of diabetes or hyperglycaemic 
crisis. 
*Fasting – no caloric intake for eight hours 
**OGTT – performed according to the WHO guidelines 
 
Metabolic states of impaired glucose regulation (previously referred to as prediabetic 
states) have also been identified. These, increase the individuals risk of progression 
to DM and developing cardiovascular disease.(11, 20, 21) They are:  
1 Impaired fasting glucose (IFG) - fasting plasma glucose of 5.6mmol/l - 6.1mmol/l 
(according to the WHO) and 6.9 mmol/l (according to the American Diabetes 
Association (ADA)). 
2 Impaired glucose tolerance (IGT) – 2hour plasma glucose in an oral glucose 
tolerance test (OGGT) of >7.8mmo/l but <11.0mmol/l. 
 
Values for diagnosing diabetes are given in table 1.3 above. The guidelines all 
recommend that:(11,18,22,37) 
I. Diagnosis be based on formal laboratory tests and not point of care bedside 
instruments. 
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II. Confirmatory tests done on a separate day (using the same modality) should 
be used to establish a diagnosis. The exception being the patient with obvious 
symptoms of polyuria, polydipsia and weight loss or in the case of a person 
presenting with hyperglycaemic crisis (Diabetic ketoacidosis (DKA) and 
hyperosmolar hyperketotic state (HHS)). 
III. If HbA1c is being used the test method must conform to certain quality 
assurance criteria. Namely: the assay must be standardised to international 
reference values as per the National Glycohaemoglobin Standardisation 
Programme (NGSP) and must also be standardised to the Diabetes Control 
and Complications Trial (DCCT). Additionally, no conditions that preclude 
using the assay must be present (these will be discussed later (section 1.1.8)). 
IV. Should results be unequivocal or discrepant results obtained after performing 
two different tests, then a 75g OGTT should be performed. 
 
Screening for T2DM should occur only within health care settings so that appropriate 
follow up can be organised should tests conducted be diagnostic of DM. Random 
screening is recommended for adults over the age of 45 years. Opportunistic 
screening during visits for other conditions and targeted screening of individuals 
identified as high risk should be performed in individuals with any of the indications 
stated in table 1.4 below.(11, 18) 
 
Screening should be performed at 3 yearly intervals if the original test is normal and 
annually should there be multiple risk factors present or if the individual has been 
diagnosed with IFG or IGT. 
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Table 1.4: Indications for DM screening/High Risk Individuals 
All adults (any age) with body mass index (BMI) ≥ 25 kg/m2 (overweight or obese), plus 
one or more additional risk factors 
Additional Risk factors: 
- Physical inactivity 
- Hypertension [blood pressure (BP) ≥ 140/90 mmHg] 
- Family history of diabetes (first degree) 
- Dyslipidaemia 
- Polycystic ovarian syndrome 
- High-risk ethnic group e.g. those of South Asian descent 
- Cardiovascular disease history 
- Gestational diabetes or baby weighing > 4 kg 
- Previous IFG or IGT 
- Other conditions associated with insulin resistance 
 
1.5 Complications 
The long term consequences of diabetes result from chronic 
hyperglycaemia.(17,20,38,39) Complications include damage to both vascular and 
nonvascular structures leading to dysfunction of multiple organ systems.(17) Non-
vascular complications comprise mainly of emergencies related to diabetes such 
as DKA, HHS, hypoglycaemia and recurrent infections.(20) Vascular disease is 
common and a major cause of morbidity and mortality of DM.(3) The vascular 
complications of DM can be further classified according to microvascular and 
macrovascular complications.(38,39) In the CODE-2 study which collated data from 
eight European studies and involving a total of 7000 people with diabetes, found 
that 72% of individuals had at least one complication and 24% had both 
microvascular and macrovascular complications.(40)  
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1.5.1 Microvascular disease 
Diabetic Nephropathy (DN)  
Chronic hyperglycaemia results in a complex series of events that cause destruction 
of the kidneys.(39) The structural and haemodynamic changes within the kidneys 
leads to a progression of events beginning with hyperfiltration and hypertrophy of the 
kidneys and ending in end stage renal failure with eventual need for dialysis (and 
possible renal transplant) if no steps are taken to intervene.(20) DN can be detected 
by screening for microalbuminuria/proteinuria at diagnosis and during follow-up.(38) 
The mainstay of treatment for the proteinuria of DN is Angiotensin Converting 
Enzyme inhibitors (ACE-I) and Angiotensin Receptor Blockers (ARB).(18, 22, 39) 
 
Diabetic Eye Disease 
This comprises Diabetic Retinopathy (DR) and cataracts. These are some of the 
leading causes of visual loss and blindness in both the developing and developed 
world.(18, 35) 
 
DR can be divided into non-proliferative DR with changes in retinal blood vessel 
integrity and permeability (microaneurysms and haemorrhages seen on fundoscopy) 
and proliferative DR with neovascularisation of the retina.(20) Treatments that reduce 
visual loss include laser photocoagulation, vascular endothelial growth factor 
antagonists and vitrectomy.(39) 
 
Diabetic Neuropathy  
Approximately 50% of patients with DM will develop neuropathy.(39) DM affects both 
the somatic and autonomic divisions of the peripheral nervous system.(38,39) 
Individuals with somatic involvement, may present with distal symmetrical 
polyneuropathy, mononeuropathies or polyradiculopathies  which may be further 
complicated by ulceration and injuries.(19, 35) 
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The manifestations of the autonomic neuropathy of DM are:(37–39) 
 Cardiovascular – resting tachycardia, orthostatic hypotension 
 Gastrointestinal – oesophageal dysmotility, gastroparesis, nausea, 
bloating, diarrhoea, faecal incontinence 
 Genitourinary – sexual dysfunction (males: erectile dysfunction, 
retrograde ejaculation; females: decreased libido, decreased 
lubrication, dyspareunia), urinary incontinence and bladder dysfunction 
 Recurrent infections 
No cure currently exists for diabetic neuropathy. Treatment consists of optimizing 
glucose control and the management of neuropathic pain and other symptoms.(20) 
 
1.5.2 Macrovascular disease 
Atherosclerosis is thought to be the main pathological mechanism by which DM 
causes macrovascular disease.(38) 
  
Coronary artery disease (CAD) 
Diabetes is an individual risk factor for CAD.(38) In the Framingham Heart Study, 
diabetes was associated with a 3-fold higher risk of myocardial infarction (MI) as well 
as substantially increased risk of hypertensive heart disease and heart failure.(41, 42)   
 
The increased risk of CAD can be attributed to the increased prevalence of traditional 
risk factors (such as hypertension, obesity and dyslipidaemia) in the diabetic 
population, as well as the presence of non-traditional risk factors.(43,46) Insulin 
resistance, hyperinsulinaemia, post-prandial hyperglycaemia and glucose variability, 
microalbuminuria, platelet hyperactivity, hypercoagullibility and chronic low grade 
inflammation are just some of the non-traditional risk factors recognised in DM.(46)  
The best outcomes are achieved by addressing all of the risk factors present and the 
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need to find the simplest and safest way to do this has become the target of many 
studies. Drugs such as Empaglifozin, a selective inhibitor of the sodium glucose 
cotransporter 2, have proven to be promising in this regard.(47) 
 
Cerebrovascular disease (CVD) 
There is a 150-400% increase in the risk of stroke and stroke related complications 
are also increased in DM.(38) 
 
Peripheral vascular disease (PVD) 
Furthermore, in addition to chronic hyperglycaemia, there are other factors that 
increase the risk of complications. Diseases such as Hypertension (HT) and 
dyslipidaemia often occur concurrently with Type 2 Diabetes Mellitus. These 
conditions may accelerate complications through a compounding effect.(18, 37, 39) In 
order to prevent complications, early diagnosis; good glycaemic control and control of 
concomitant risk factors is recommended. A number of different parameters can be 
used to assess severity of disease and disease control.(18, 37) 
 
1.6 Treatment of T2DM 
1.6.1 Lifestyle intervention 
Lifestyle modification is arguable the most important intervention in the treatment of 
DM. It should target glycaemic control, modification of cardiovascular risk factors and 
weight reduction.(41, 42) These can be achieved through: 
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Medical Nutrition Therapy  
With the assistance of a dietician and in some cases behavioural modification therapy, 
individualized diets that take into account patients nutritional requirements, weight loss 
goals, budget, personal choice and cultural /religious practices can be designed.(49) 
 
Exercise 
To ensure optimal results, exercise too should be approached using a multidisciplinary 
team. A tailor-made exercise program that fits the patient’s lifestyle, preference and 
physical limitations is most likely get better results.(48) SEMDSA has adopted the WHO 
recommendation of 150 minutes per week of moderate intensity exercise.(2)  
 
Smoking Cessation 
Smoking is an independent risk factor for cardiovascular disease.(50) In smokers with 
diabetes the cardiovascular disease risk is cumulative. Smoking cessation has been 
proven to improve control of DM and co-morbidities such as Hypertension; and also to 
decrease incidence of complications.(51–53) Many patients find it very difficult to quit 
alone. Assistance with counselling, pharmacological and non-pharmacological aids 
may be required.(54) 
 
Alcohol Consumption 
The harmful effects of excessive alcohol use are well known.(2) Moderate alcohol use 
has no adverse effects on DM control and has even been demonstrated to be 
cardioprotective.(55, 56) Identifying patients with excessive alcohol use/abuse and 
assisting them with appropriate assistance is thus an important aspect of management. 
SEMDSA recommendations for alcohol consumption is one unit a day for females and 
two units a day for males. Avoidance of alcohol should be encouraged in persons who 
are obese and those with hypertriglyceridaemia.(22) 
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1.6.2 Pharmacological Treatment 
A number of different oral and injectable medications and insulins are available for the 
treatment of DM. Most guidelines advocate a stepwise approach to the treatment of 
DM beginning with one oral medication and progressing to combination oral treatment 
and eventually insulin based treatments.(18, 21, 50) 
 
Metformin is the mainstay of treatment, and should be used in the majority of patients, 
the only exceptions being severe renal failure and intolerable side effects.(37,57,58) 
Metformin is recommended as the first step in many guidelines for the treatment of 
T2DM including the 2017 SEMDSA guideline and the 2017 American Diabetes 
Association Guidelines.(22,37) Metformin has also proven useful in individuals with 
insulin resistance in preventing the progression to DM.(59) Patient monitoring should 
occur at three monthly intervals and treatment regimen should be intensified until target 
Glycated Haemoglobin (HbA1c) has been achieved.(22)  
 
Dual, triple and complex treatment regimens involve the addition of one or more of the 
following: sulphonylurea, pioglitazone, DDP-4 (dipeptidyl peptidase-4) inhibitor, SGLT-
2 (sodium-glucose linked transporter 2) inhibitor, GLP-1 (glucagon-like-peptide-1) 
agonist and various insulin preparations. The choice of additional agent should be 
individualized according to patient requirements and patient preference, as while all 
drugs have been proven to be efficacious with regard to lowering blood glucose they 
differ in side effect profiles and additional benefits such as weight loss and 
cardiovascular protection.(22, 57)  
 
Certain presentations may require starting with combination therapy (HbA1c >9% 
without severe decompensation) or even with insulin (severe decompensation: 
ketoacidosis, HbA1c >11%, fasting plasma glucose >15mmol/l, weight loss >5% and 
severe polyuria and polydipsia).(18) 
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Treatment of concomitant medical conditions such as hypertension and dyslipidaemia 
is important in the patients with DM and will be discussed elsewhere in this text. 
Additionally, the use of aspirin is not advocated for primary prevention of 
cardiovascular disease in patients with T2DM but strongly recommended (dose of 
75mg to 162mg per day) for secondary prevention in patients with established 
cardiovascular disease.(22,37) Alternate platelet aggregator inhibitors can be offered to 
patients with established cardiovascular disease who cannot tolerate aspirin.(22) 
 
1.6.3 Surgery 
Gastric and bariatric surgeries have proven to have beneficial effects in the control of 
obese diabetics and in the prevention of complications.(21, 53) However, surgery is 
costly and comes with the possibility of serious complications. The SEMDSA 
guidelines therefore only recommends surgery in carefully chosen individuals: those 
with a BMI ≥ 35kg/m2 and in those patients with BMI between ≥ 30 kg/m2 who fail to 
achieve control of glucose with adequate medication and lifestyle modification. 
Bariatric surgery should only be carried out under the supervision of a 
multidisciplinary team.(22) 
 
1.7 Targets for Treatment and Guidelines 
Proper organisation and management of resources ensure that people get the best 
treatment possible. To this effect, most diabetic societies have proposed guidelines to 
assist clinicians. The 2012 SEMDSA guidelines were in use when this study was 
proposed. Newer guidelines have subsequently been published in 2017.(18, 22) The 
following targets for treatment have been identified in the SEMDSA guidelines. 
 
1.7.1 Glycated haemoglobin (HbA1c) levels 
HbA1c is a stable haemoglobin variant which is formed through the irreversible non-
enzymatic glycation of one or both N-terminal valines of the β=chains during exposure 
of haemoglobin to plasma glucose.(61) It is a measure of the average blood glucose 
over the preceding 10-12 weeks (lifespan of a red blood cell).(62) The fraction of 
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glycated haemoglobin increases in a predictable manner with the increase in blood 
glucose and an estimated average glucose level can thus be ascertained.(41) 
 
The reliability of the HbA1c test can be affected by a number of factors that affect the 
haemoglobin compound, the red blood cell, the glycation process and the assay used 
to perform the test.(63) The factors are tabulated below. 
 
Table 1.5: Factors Affecting HbA1c: 
Aspect Affected Decrease HbA1c Increase HbA1c Variable Effect on 
HbA1c 
Haemoglobin   Methaemoglobin 
Haemoglobinopathies 
Foetal Haemoglobin 
Erythropoiesis Iron, Vitamin B12 or 
erythropoietin administration, 
Chronic Liver Disease 
Reticulocytosis  
Decreased erythropoiesis 
Iron deficiency 
Vitamin B12 deficiency 
 
Erythrocyte Decreased erythrocyte 
lifespan 
Splenomegaly 
Rheumatoid Arthritis 
Haemoglobinopathies 
Drugs (Antiretrovirals/ 
Dapsone/ Ribavarin) 
Increased erythrocyte 
lifespan 
Splenectomy  
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Glycation Increased erythrocyte pH 
Certain haemoglobinopathies 
Ingestion of Aspirin, Vitamin 
C and Vitamin E 
Decreased erythrocyte pH 
Chronic renal failure 
Alcoholism  
Genetic Determinants 
Assay Hypertriglyceridaemia  Carbamylated 
haemoglobin 
Alcoholism 
Hyperbilirubinaemia 
Chronic opiate use 
Large doses of Aspirin 
Haemoglobinopathies 
*Adapted from Gallagher ET. Al 
The use of targeted HbA1c levels to reduce the level of complications of diabetes has 
been evaluated in a number of studies. The following landmark studies are important 
to take note of: 
Diabetes Control and Complications Trial (DCCT) 
Performed in the late 1980’s and early 1990’s, this trial aimed to assess the effects of 
intensive glucose control in T1DM as measured by reduction in HbA1c to a level 
comparable to the non-diabetic population on micro and macrovascular complications. 
The study consisted of 1441 people with T1DM and randomized them to the control 
(continuation of regular treatment) and intervention arm (intensive increase in 
treatment to achieve near normal HbA1c). The mean HbA1c achieved was 7% in the 
intervention group and 9% in the control group. The DCCT demonstrated that tighter 
glycaemic control resulted in a 35-76% decrease in early microvascular complications 
of DM. The two major adverse events noted was increased frequency of 
hypoglycaemia and weight gain in the intervention arm. A review of the same cohort 
of patients 30 years later in the Epidemiology of Diabetes Interventions and 
complications study (EDIC) revealed that though average HbA1c had become 
comparable in the control and intervention arms of the DCCT, the intervention arm had 
lower rates of both microvascular and microvascular complications. This sustained 
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response to early intensive glucose control  was attributed to “molecular memory” also 
known as legacy effect or metabolic memory.(44) 
 
United Kingdom Prospective Diabetes Study (UKPDS) 
The main aim of the UKPDS was to assess the impact of intensive glycaemic control 
on the incidence of complications. The cohort comprised of 5102 subjects in 23 centers 
throughout the United Kingdom (UK). Individuals were randomized to either, intensive 
therapy (with target fasting glucose of 6.0mmol/l) and a conventional treatment arm 
(target fasting glucose <15mmol/l and keeping patients asymptomatic). Subjects were 
followed for a duration of 10years. Composite end points which included any 
microvascular events, macrovascular events and diabetes related deaths were 
assessed. On conclusion of the study the UKPDS demonstrated a 25% reduction in 
microvascular complications and a trend towards a reduction in macrovascular 
complications. However the latter was not statistically significant.(64) 
 
Action to Control Cardiovascular Risk in Diabetes (ACCORD) 
The ACCORD trial undertook to specifically address the question of whether intensive 
glycaemic control with target HbA1c <6.0% as compared to standard control HbA1c of 
7.0-7.9%, would improve cardiovascular outcomes in middle-aged or older people with 
T2DM. They recruited more than 10000 participants and were meant to follow them up 
for a period of five years. The study was however, terminated after three and a half 
years due to increase in all-cause mortality in the intensive arm group.(65) 
 
Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified 
Release and Controlled Evaluation (ADVANCE)  
The ADVANCE trial was structured in a similar manner to the UKPDS trial and looked 
at similar outcomes. HbA1c levels of <6.5% were achieved in the intensive treatment 
group in contrast to the DCCT and UKPDS study and without the increase in mortality 
seen in the ACCORD trial. ADVANCE concluded that intensive glucose control to 
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<6.5% had no impact on macrovascular disease. However, there was a statistically 
significant effect on microvascular disease, particularly nephropathy.(45) 
 
Veterans Affairs Diabetes Trial (VADT)  
This trial had the same objectives as the trials discussed above. The study assessed 
intense glucose control in an older population. Mean HbA1c in the intensive group after 
5.6 years of treatment was 6.9% in comparison to 8.4% achieved in the control group. 
The VADT trial demonstrated a reduction in cardiovascular events of 17% but at the 
risk of increase in frequency of severe hypoglycaemic events. There was no impact on 
overall mortality. 
 
10 year follow of these participants revealed a sustained decrease in cardiovascular 
events with 8.6 fewer events per thousand when compared to the control group.  This 
finding is similar to that seen in the follow up of DCCT (Epidemiology of Diabetes 
Interventions and Complications (EDIC)).(66) 
 
Informal review of these studies and with formal meta-analysis which include the above 
and other trials it is evident that early, intensive glycaemic control reduces the risk of 
major complications.(65, 67) Although the ACCORD trial was stopped prematurely due 
to increase in mortality in the intensively controlled group (HbA1c <6.5%), this has not 
been noted in any of the other studies. What must also be kept in mind is that the 
majority of studies show this benefit couple with increases in severe though non-fatal 
hypoglycaemic events and weight gain.(67) In the real world treatment of people with 
DM it is thus imperative that the clinician take into consideration all of these facts and 
individualizes the HbA1c target to balance optimal benefit with lowest risk.(67) This 
approach is also advocated by both the ADA and SEMDSA guidelines.(18, 21) 
 
The 2012 and 2017 SEMDSA guidelines recommends that HbA1c levels be tested 3 
months after any initiation of or change in medication, and after 6 months if the last 
measured HbA1c was within target range.(18, 22) 
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Table 1.6: Glycated Haemoglobin Target: 
Young 
Low risk 
Newly diagnosed 
No cardiovascular disease 
 
 
<6.5% 
Majority of patients <7% 
Elderly 
High risk/ Established CVD 
Hypoglycaemic unaware 
Poor short term prognosis 
 
 
<7.5% 
 
 
1.7.2 Blood Pressure (BP) 
Blood pressure measurement is a critical aspect in the care of patients with Diabetes 
Mellitus. Elevated blood pressures have been demonstrated to be an increased risk 
factor for both microvascular and macrovascular disease.(67) In the general population, 
blood pressures of >115/75mmHg have been shown to confer a higher risk for 
cardiovascular events and mortality. This doubles for every 20mmHg increase in 
systolic blood pressure and 10mmHg increase in diastolic blood pressure.(68) A number 
of trials have evaluated the importance of blood pressure control in DM. 
 
I. The ACCORD trial monitored blood pressure lowering in patients with T2DM. 
ACCORD did not demonstrate any significant reduction in overall morbidity and 
mortality with intensive BP control. However, it did show reduction in stroke 
occurrence and an increase in adverse events in the patients with systolic blood 
pressure lower than 120mmHg caused by hypotension, syncope and 
bradycardia.(69)  
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II. The UKPDS study randomized patients to a goal blood pressure of <150/85mmHg 
(tight group) and <180/105mmHg (less tight group). Follow –up of participants after 
8-9 years revealed a 24% reduction in all diabetes related end points. Notably, there 
was a 44% reduction in stroke rate and 32% reduction in deaths related to diabetes 
in the lower blood pressure group. Of mention is a 34% decrease in occurrence of 
retinopathy in the higher blood pressure group.(64) 
 
III. The ADVANCE trial also showed significant risk reduction for microvascular and 
macrovascular complications; cardiovascular deaths and all-cause mortality in the 
group with intensive BP monitoring.(45) 
 
IV. The Hypertension Optimum Treatment (HOT) trial demonstrated that a diastolic 
blood pressure of <80mmHg is cardio-protective and reduces risk of other diabetic 
complications as well.(70) 
 
Antihypertensive drugs such as ACE-I, ARBs, thiazide diuretics, calcium channel 
blockers (CCB) and beta-blockers have been shown in studies to reduce microvascular 
and cardiovascular complications.(71) Though all of these drugs have proven to be 
effective through their effects on lowering BP, some have proven to have additional 
benefits.(72)  ACE-I and ARB’s have shown to have advantages effects in the treatment 
of proteinuria, DN, heart failure and myocardial infarctions.(37, 66–68) Multiple trials have 
demonstrated the benefit of diuretics and beta blockers in cardiac failure, myocardial 
infarctions and stroke.(71,72) CCB have additional benefit in preventing stroke and its 
complications.(71) 
 
BP in DM individuals is usually difficult to control and multiple agents may be 
required.(71) The 2017 SEMDSA guidelines recommend initiation of treatment for 
hypertension if BP >140/90.(22) The following are recommended: 
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 In patients without albuminuria: monotherapy with either thiazide-like diuretic, 
ACE-I, ARB or CCB is suitable.  
 Diuretics and CCB are recommended as first line treatment in the black 
population 
 The preferred diuretic is Indapamide (thiazide like diuretic) 
 Compelling indications such as diabetic kidney disease, stroke, heart failure and 
ischaemic heart disease necessitate the use and avoidance of specific anti-
hypertensive drugs. 
Table 1.7: Blood Pressure Targets:(18,22) 
*In patients with a high risk of stroke, a Systolic Blood Pressure of <130 mmHg 
should be targeted if this can be achieved without undue treatment burden 
 
1.7.3  Lipids 
T2DM leads to altered lipid metabolism with mainly increases in triglycerides (TG) and 
decreases in HDL-cholesterol.(74) In addition, increased circulating lipid cause 
elevations in blood glucose. Lipid abnormalities contribute to accelerated 
atherosclerosis and cardiovascular risk, thereby increasing the morbidity and mortality 
of T2DM.(75–77) The Heart Protection Study (HPS) and the Collaborative Atorvastatin 
Diabetes Study (CARDS) were two of the largest trials that demonstrated reductions 
in of cardiovascular disease with reduction LDL- cholesterol.(76) LDL-cholesterol 
lowering drugs (such as Statins) have been shown to reduce the risk of major coronary 
 2012 2017 
Systolic BP 120 - 140 mmHg 130 – 140 mmHg 
Diastolic BP 70 – 80 mmHg 80 – 90 mmHg 
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events 15-40%.(78,79) Controversy exists with regards to the use of fibrates, however, 
in clinical practice these drugs have proven useful in some individuals.(80) 
 
The IMProved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE-
IT)  demonstrated the efficacy of combination Ezetimibe and statin therapy in improving 
cardiovascular outcomes.(76,79) Other drugs, PSCK-9 inhibitors, microsomal triglyceride 
transport protein inhibitor, apolipoprotein A1 mimetics, and antisense oligonucleotide 
against Apolipoprotein B have also proven useful in the treatment of dyslipidaemia. 
However, these are still in trial phase and long term efficacy is uncertain.(79) 
 
The 2017 SEMDSA guidelines recommend measurement of lipids at diagnosis with 
treatment targeted at the abnormalities identified. During initial titration of treatment, 
lipid measurements should be performed every three months. Once targets have been 
achieved, monitoring should occur on a yearly basis.(18) 
 
Table1.8: Lipid Targets: 
 
 
  
 
 
 
 
 
 
Total Cholesterol < 4.5 mmol/l 
Triglycerides:  < 1.7 mmo/l 
HDL cholesterol: > 1.2 mmol/l  for women 
> 1.0 mmol/l  for men 
LDL cholesterol: < 1.8 mmol/l 
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1.7.4  Obesity 
The concept of obesity as a heterogeneous entity has already been discussed. IRO 
individuals have been proven to have significantly increased cardiovascular risks. 
Though the MBO individual seems to have little to no risk in short term studies, long 
term follow-up suggests that these individuals do subsequently develop features of 
insulin resistance/DM as well as other complications.(81) Furthermore, it is not just 
increased weight, but weight distribution that is important. Increase in visceral rather 
than subcutaneous fat has proven to be a metabolic and cardiovascular risk factor.(82, 
83) 
 
Thus, as stated earlier, intervention to reduce complication, should target all obese 
individuals. Interventions may include nutritional and exercise programs, behavioural 
therapy, pharmacotherapy and bariatric surgery. 
 
Table1.9: Obesity Target: 
   
 
 
 
 
 
 
 
Waist Circumference 
      Women <80cm 
      Asian men <90cm 
      Other men <94cm 
BMI target of <25 kg/m2 
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1.8 Diabetes and Infectious Diseases  
Infectious diseases comprise the majority of the health care burden in Africa.(84) With 
the rise in NCD in this region the interaction between the two cannot be ignored. Of 
note, Human Immune Virus (HIV) and its treatment has been implicated as a cause 
of DM.(85–87) The postulated mechanisms through which this occurs is:(85,88) 
1.8.1. Changes in glucose homeostasis through: 
 Insulin resistance is the main pathogenic factor 
 Concomitant infection with Hepatitis C increases hepatic steatosis and TNF-α  
 Visceral adipose tissue accumulation 
 Longer duration of HIV, low-CD4 count and high HIV viral load  
 
1.8.2 Changes caused by Antiretroviral Drugs 
 Protease Inhibitors interfere with GLUT-4 mediated glucose transport causing 
insulin resistance and reduction in insulin secretion. 
 Protease inhibitors also inhibits peroxisomal proliferator activator γ through 
interaction with cellular retinoic acid-binding protein type 1 release of free fatty 
acids and insulin resistance. 
 Nucleoside reverse transcriptase inhibitors cause mitochondrial dysfunction, 
lipodystrophy and insulin resistance. 
 
Like HIV, DM increases the risk of infections such as tuberculosis (TB). In turn, TB 
treatment and outcomes may be adversely impacted by the presence of DM.(87,89,90) 
Furthermore, both HIV and TB treatment may make control of DM difficult.(83, 84, 86)  
There are currently no local studies assessing the incidence and prevalence of 
diabetes in patients who are HIV positive and on treatment.  
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1.9 Review of literature pertaining to achievement of targets in DM 
1.9.1 South African Studies 
Sub-Optimal Management of Type 2 Diabetes Mellitus – A Local Audit.(92) 
This study conducted in 2009 reviewed 150 patients from the three academic 
hospitals in Johannesburg and assessed control of glucose, blood pressure, lipids 
and weight in patients with T2DM on both oral hypoglycaemic agents and insulin. 
 
The mean HbA1c in this population was 8.7% with only 30.7% of patients reaching 
target HbA1c of <7%. Of the 150 patients, 21.3% reached target SBP <130mmHg, 
40.2% reached target DBP <80mmHg, 50.7% of patients achieved target LDL-
cholesterol of <2mmol/l and 70.2% of patients were classified as overweight and 
obese with the majority having abdominal circumferences greater than the 
recommended values. 
 
The achievement of glycaemic, blood pressure and LDL cholesterol targets in 
patients with type 2 diabetes attending a South African tertiary hospital 
outpatient clinic.(93) 
In 2013, Pinchevsky et al reviewed clinic records of 261 patients attending the 
diabetic clinic at Charlotte Maxeke Johannesburg Academic Hospital. These patient 
records had also been audited in 2009 and a comparison of glycaemic control, BP 
and LDL-cholesterol levels between the two audits was carried out. The cohort 
consisted of mainly females (55%) and African patients (42.9%). Mean HbA1c was 
8.5% in 2009 and 8.7% in 2013 with target HbA1c of <7% achieved in 25.4% of the 
cohort in 2009 and 15.5% in 2013. BP target of <140/90mmHg was achieved by 
35.9% in 2009 and 49.6% in 2013. LDL-cholesterol targets were achieved in 72.7% 
in 2013 as compared to 47.7% in 2009. 
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Diabetes guidelines and clinical practice: is there a gap? The South African 
cohort of the International Diabetes Management Practices Study.(58) 
This article reviewed the South African cohort of an international, multicentre cross-
sectional review of control in DM patients in private care settings. The population of 
this cohort was mainly Caucasian males in contrast to the studies conducted in public 
health care centres. Target achievement assessment was only carried out for HbA1c 
levels. However, means were reported for BP (132.9/80) and waist circumference 
(108.3 for males and 101.7 for females). Mean HbA1c for T2DM was 8.1% with 
patients on insulin-only having a higher mean HbA1c than those on oral agents alone 
(9.02% vs 7.62%).  
 
1.9.2 Studies Conducted in Other Countries 
Prevalence of Type 2 Diabetic Patients Within the Targets of Care Guidelines in 
Daily Clinical Practice: A Multi-Centre Study in Brazil.(94) 
Over the period of May 2000 to May 2001 a multi-centre, cross sectional study was 
conducted in Brazil. The study involved thirteen public endocrine clinics in urban 
areas which served a mainly low income population. Clinic records of 2233 patients 
was analysed to assess weight, BMI, HbA1c, BP and cholesterol. Mean age of 
patients was 59.2% and the sample population was predominantly female (60%). 
One third of patients were obese and 42.1% were overweight. 46% of patients 
achieved glycaemic targets. However, it is important to note that the rate of 
glycaemic target achievement was higher in patients receiving dietary or oral 
treatment than in patients on insulin alone or insulin-oral combination (67% & 56% vs 
35% and 39%).  Targets for SBP, DBP and LDL-Cholesterol were met by 28.5%, 
19.3% and 20.6% of patients respectively. 
 
 
 
 
30 
 
Glycemic control in diabetic patients in King Khalid University Hospital (KKUH) 
– Riyadh – Saudi Arabia.(95) 
Medical records of patients collecting treatment from the King Khalid university 
hospital pharmacy were reviewed over a one year period. Subjects included in the 
study numbered 1520. Majority were female, over the age of 40 (90%) and obese 
(90%). Glycaemic control (HbA1c <7%) was achieved in 40% of patients, target LDL-
cholesterol in 24.6% of patients and SBP BP targets in 50% and DBP target in 72%.  
 
 
Glucose, Lipid, and Blood Pressure Control in Australian Adults With Type 2 
Diabetes. The 1999-2000 AusDiab. (96) 
The baseline data collection for the Australian Diabetes, Obesity and Lifestyle study 
also showed very poor achievement of targets for glycaemic control, BP and lipids in 
the large population based survey. Over the twelve year follow-up, there was little 
improvement in target HbA1c and BP achievement. However there was marked 
improvement in the achievement of LDL-cholesterol targets.(97) 
 
Review of the American National health and nutrition surveys (NHANES) data and 
the European Guideline Adherence to Enhance Care Study (GUIDANCE) also reveal 
poor levels of achieving DM targets.(98, 99) 
 
 
Other significant points to note from review of these and other studies are: 
1. Individuals with poorer control include younger patients, women and patients on 
insulin based regimens.(100–102) 
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2. Reasons cited for poor achievement of targets include: non-compliance to 
lifestyle intervention and prescribed treatment, low income with poor access to 
healthcare and monitoring and inertia in escalating treatment.(95,103,104) 
 
 
In summary, DM is one of the NCD that is increasing exponentially worldwide and 
has been recognised by national and international institutions as an area of concern. 
Uncontrolled hyperglycaemia leads to significant morbidity and mortality and has far-
reaching social and economic consequences. Comorbidities such as hypertension, 
dyslipidaemia and obesity further increases the risk of complications. In South Africa, 
as in many other regions, guidelines have been developed to assist with screening 
and treatment. Still, in most places, achievement of targets set out within guidelines 
is low. The purpose of this study is to assess whether the patients at the Helen 
Joseph Diabetic Clinic are achieving said targets.  
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2 PROTOCOL 
2.1 Study Objectives 
2.1.1 Primary Objectives 
To evaluate the degree to which target HbA1c levels are achieved in accordance with 
The 2012 Society for Endocrinology, Metabolism and Diabetes of South Africa 
(SEMDSA) guidelines.  
 
 
2.1.2  Secondary Objectives 
a. To determine if targets for Blood Pressure in patients attending the Diabetic Clinic 
are achieved.  
b. To determine if goals for serum lipids in patients attending the Diabetic Clinic are 
achieved.  
c. To determine the prevalence of obesity of patients attending the Diabetic Clinic 
based on the World Health Organization definition of obesity. 
d. To determine the prevalence of metabolic syndrome of patients attending the 
Diabetic Clinic based on the Harmonized definition of the metabolic syndrome. 
e. To assess whether patients attending the Diabetic Clinic adhere to lifestyle 
modification. The following factors will be looked at: smoking, alcohol 
consumption and exercise 
 
 
2.2 Methods 
 
2.2.1 Study Design 
Retrospective Cross-Sectional Clinical Audit for the defined date range 1st March 
2013 to 30 April 2015. 
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2.2.2 Study population 
 
a. All established type 2 diabetic patients attending the diabetic clinic 
b. Exclusion Criteria 
i. Less than 5 years since diagnosis 
ii. Patients on oral hypoglycaemic agents other than Metformin 
 
 
2.2.3 Setting 
The Diabetic Clinic Helen Joseph Academic Hospital 
 
 
2.2.4 Patient recruitment 
a. Sample size : 30 patients 
 
b. Sample selection: 300 consecutive patients who attended the Diabetic Clinic at 
the Helen Joseph Hospital during the period 1st March 2015 to 30th April 2015 
 
 
2.2.5 Data being collected 
All data being collected are done routinely at the clinic visit. 
a. Demographic – age, race and gender 
b. Year of diagnosis of diabetes 
c. Year at which insulin was started 
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d. Smoking history. This is recorded in yes/no format in the patient files and is not 
quantified 
e. Alcohol use- This is recorded in yes/no format in the patient files and is not 
quantified 
f. Exercise- This is recorded in yes/no format in the patient files and is not quantified 
g. List of medications used by patient as recorded at last clinic visit 
h. Height in meters(assumed to have been collected using a standardize height 
meter) 
i. Weight in kilograms using a standard scale placed on the floor. Patients are 
weighed standing barefoot without any support. 
j. Body mass index was calculated as a function of the measured height and weight 
using Quetelet’s formula = weight (kg)/height(m) x height(m) 
k. Abdominal circumference recorded with the use of the IDF measuring tape 
l. Blood Pressure was measured with an automated sphygmomanometer. An 
average of the blood pressures from the last 3 visits were assessed in order to 
compensate for white coat hypertension 
m. Latest HbA1c recorded 
n. Last Serum lipogram recorded 
 
 
2.2.6 Data confidentiality 
No patient names or hospital number will be recorded on data sheets. Data sheets 
(see Appendix A) will be assigned a study number only. Any links between the study 
numbers, patient initials and identity of patients will be kept separate. Data will then 
be accessible to the supervisor, statistician and myself.  
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2.2.7 Endpoints 
Endpoint of the study will be marked by selection of 300 patients 
 
 
2.2.8 Sources of Bias  
a. Sampling:  As consecutive patients will be included in the study, it is purely chance 
that determines inclusion.  Thus the audited sample is rarely fully representative of 
the general population. 
b. Selection Bias: The Specialist Diabetic Clinic is a referral clinic that accepts 
patients who are poorly controlled with or without established target organ 
damage. This will result in higher average HbA1c analysis.  
c. Measurement Bias: Reliability of observations/measurements taken by  nursing 
sister as well as poor record keeping by doctors 
 
 
2.2.9 Confounding variables/Limitations 
a. Patient’s non-compliance with regards to medication will not be assessed in this 
retrospective audit.  
b. Patient’s non-compliance with regards to exercise and other lifestyle modifications 
will not be assessed in this retrospective audit.  
c. Smoking and drinking of alcohol will not be quantified. 
d. Duration and frequency of exercise will not be assessed. 
e. Patient’s adherence to diet will not be assessed in this retrospective audit. 
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2.2.10 Study Strengths 
a. All the necessary information captured should be available as part of standardised 
care 
b. The blood results are standardised and performed by the same laboratory 
(National Health and Laboratory Service based at Helen Joseph Academic 
Hospital) 
c. Using the data sheet, a single researcher will collect the data from the patient 
records ensuring standardisation and reliability. 
 
 
2.3 Data Analysis 
 Data will be captured on physical paper and then captured electronically on (the 
program that you using) 
 Date from (the program that you using will be exported to Excel  where the 
following Basic Data analysis will be done   
 Descriptive analysis of the demographics 
 Male and female breakdown as a percentage of study population 
 Age will be shown as median and range 
 Duration of treatment will be shown as median and range 
 HbA1c, Blood pressures and waist circumference will be shown as range and 
median 
 Prevalence of metabolic syndrome will be reported as percentage 
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2.4 Approval / Ethics  
Approval will be obtained from the relevant governing committees: Ethics Committee 
Helen Joseph Hospital and University of the Witwatersrand Ethics Committee. 
 
 
2.5 Funding 
The study was self-funded. No cost will be imposed on the hospital or the patient. 
The results will be obtained from clinical and hematological records, the patients will 
be seen at their routine visits and will not be required to come in for a second visit. 
Any funds required for paperwork (data sheet) will be provided by the doctor 
conducting the audit.  
 
 
2.6 Timing 
The study will commence once approval is received.  The expected duration of the 
audit is 10-12 months. This will be subject to the clinical commitments of the primary 
investigator, hence the time frame maybe shortened or lengthened. 
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The following Gantt chart outlines the audits timeline:   
 
 
Mar
-15 
Apr-
15 
May
-15 
Jun-
15 
Jul-
15 
Aug
-15 
Sep
-15 
Oct-
15 
Nov
-15 
Dec
-15 
Jan-
16 
Feb
-16 
Literature 
Review 
            
Protocol 
Preparation 
            
Protocol 
Assessment 
 
           
Ethics 
Application 
  
          
Data 
Collection 
And Write 
Up 
            
 
 
2.7 Consent Form  
The audit is retrospective and all information that will be recorded audit is done at a 
routine follow up visit.  
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ABSTRACT 
Background:  
The risk of complications from Type 2 Diabetes Mellitus (T2DM) is high. Achieving 
targets reduces the morbidity and mortality. This study aims to assess whether patients 
at the Helen Joseph Hospital’s Diabetic Clinic are meeting the 2012 SEMDSA targets 
for diabetes. 
 
Methods:  
A Retrospective Clinical Audit was carried out. The files of 321 patients with T2DM 
were reviewed. Glycated haemoglobin (HbA1c), Blood pressure, abdominal 
circumference and lipograms were assessed. 
 
Results:  
The study population compromised majority black (n=143; 44.6%) and coloured 
(n=109; 34%) patients and  was predominantly female (n=200; 62.3%).The mean age 
was 59.4 years (SD 9.9y). 89.1% (n=286) had Hypertension; and 82.2% (n=264) 
dyslipidaemia. The metabolic syndrome criteria was fulfilled by 266 (91.2%) patients. 
The majority did not exercise (n=174; 56.3%). A small amount smoked (n=39; 12.5%) 
and used alcohol (n=33; 10.6%).  Mean HbA1c was 9.5% (SD 2.4; range 3.9 – 16.9%). 
Only 49 (15.3%) achieved the target HbA1c. Target Blood Pressure was achieved by 
72 patients (25%). LDL target was achieved by 71 (22.6%) and abdominal 
circumference by 32 (11%) patients. 
 
Conclusions:  
Despite adequate protocols and access to tertiary medical care, a very small 
percentage of patients are achieving proposed targets. The reasons for this is likely 
multi-fold and further analysis is required to assess these.  
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INTRODUCTION 
The global burden of non-communicable diseases (NCD) is rapidly escalating.(1) 
More than 63% of annual global deaths can be attributed to NCD’s with the majority 
occurring in low to middle income countries.(2) The impact on society, the economy 
and the health sector is immense and could be crippling if not attended to.(2–6)   
Diabetes Mellitus (DM) is one of the four areas listed for intervention by the World 
Health Organisation (WHO) and the United Nations (UN).(1, 2, 5)  
 
The 2015 International Diabetes Federation (IDF), worldwide estimated prevalence of 
adults DM is 415 million (8.8%) and this number is estimated to rise to 642 million by 
the year 2040.(7) Approximately 75% of these people live in middle to low income 
countries.(7) The scarcity of nationwide data for the majority of African countries 
makes the estimates for Africa uncertain.  
 
Nevertheless, from available data the 2015 IDF estimated prevalence of DM in Africa 
is 3.2%. In addition, an estimated 66.7% of these people remain undiagnosed, the 
largest proportion in any IDF region.(7) In South Africa, the IDF estimated prevalence 
of DM is 7% (2.3 million South Africans) and 61.1% remain undiagnosed. When 
compared to the  2010 IDF estimate for DM in South Africa  (4.5%)(8) , this equates to 
a greater than 60% increase in the prevalence of DM in just 5 years.  
 
This rapid increase in the number of people with DM is a worldwide phenomenon 
with multiple underlying causes, including: rapid urbanisation, increasing age of the 
world’s population and the rapid rise of obesity and the metabolic syndrome. The 
great concern over this rapid rise stems from the widespread impact of this disease 
on individuals, families, communities and nations.(3,7) According to IDF estimates, 
11.6% of global health expenditure is used for DM.(7) DM is also one of the leading 
causes of death worldwide and in South Africa was reported as the cause of death, in 
5% of deaths in 2016.(9) 
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Early recognition, diagnosis and implementation of treatment, continuous access to 
appropriate medications, treatment of concomitant medical problems and vigilant 
screening and recognition of complications is imperative in the management of DM. 
For this reason, Diabetic Societies worldwide have proposed guidelines to assist 
clinicians.(10, 11) Still, in most places, achievement of targets set out within guidelines 
is low. The purpose of this study is to assess whether the patients at the Helen 
Joseph Diabetic Clinic are achieving said targets.  
 
AIMS 
The primary aim of this study was to evaluate if target HbA1c levels are achieved 
among patients attending the Diabetic Clinic. Secondary objectives were to 
determine if targets for Blood Pressure, waist circumference and serum lipids were 
being achieved in these patients. Lastly, to determine the prevalence of obesity 
based on the WHO definition and the prevalence of the metabolic syndrome based 
on the Harmonized definition of the metabolic syndrome. 
 
METHODS 
Study Design 
A Retrospective Cross-Sectional Clinical Audit of the Helen Joseph Academic 
Hospital Diabetic Clinic for the defined date range of the 1st March 2015 to 30 April 
2015 was conducted. Records of all patients attending the diabetic clinic assessed. 
Records of patients with type 1 diabetes (T1DM) were excluded. T2DM patients not 
on insulin metformin were excluded from the study as these patients are usually 
followed up at the hospital medical out patients (MOPD) clinic and only referred to 
the Diabetic Clinic when insulin initiation is required. Records of patients with 
established T2DM (greater than 5 years duration) and who were on insulin-only 
therapy or insulin-metformin combination therapy were included in the study. The 
records of 321 patients fulfilled inclusion criteria and were entered into the data 
collection set. Each file was given a study number. 
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Data Collection 
Demographics and other descriptive characteristics were obtained from institutional 
records. The list of medications prescribed at the last clinic visit was used. As per 
records, information on exercise, smoking and alcohol use are noted in a yes/no 
format without being quantified and was thus recorded as such.  
 
Clinical parameters are measured by nursing staff on duty at every visit and inter-
observer variability is possible. Height is measured using a standardised height 
meter. Weight using a standardised scale is measured with patients standing 
barefoot without support. Body mass index (BMI) is calculated from the patients 
weight and height using Quetelet’s formula (weight (kg)/Height (m) x Height (m)). 
Abdominal circumference is measured using the International Diabetes Federation 
(IDF) measuring tape placed at 2cm above the anterior superior iliac crest with the 
patient standing. Blood Pressure (BP) is measured using the Mindray vs-800 
calibrated automatic sphygmomanometer. An average of the last three 
measurements was used in order to compensate for the phenomenon of white coat 
hypertension. 
 
As Helen Joseph Hospital is a public sector hospital, blood samples are processed 
by the National Health Laboratory Services (NHLS). The last recorded glycated 
haemoglobin (HbA1c) value and random serum Lipograms were used for analysis. 
 
Data was recorded on data sheets and the inputted into the Research Electronic 
Data Capture (RedCap) web based application. Once all data was recorded, a data 
report formed in RedCap was transferred to Microsoft Office Excel for analysis. 
 
Statistical and Data Analysis 
Descriptive analysis of the data was carried out as follows. Categorical variables were 
summarised by frequency and percentage tabulation, and illustrated by means of bar 
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charts.  Continuous variables were summarised by the mean, standard deviation, 
median and interquartile range, and their distribution illustrated by means of 
histograms. The prevalence of patients who met each of the treatment goals was 
estimated, together with 95% confidence intervals. The association between target 
achievement and insulin regimen was analysed by means of a chi-squared test. Data 
analysis was carried out using SAS version 9.4 for Windows.  The 5% significance 
level was used throughout.   
 
RESULTS 
Demographics 
The study population comprised 321 patients aged 30 to 88 years old, with a mean 
age of 59.4 years (SD 9.9). Complete demographic data can be seen in Table 1. 
The cohort compromised majority black (n=143; 44.6%) and coloured (n=109; 34%) 
patients. This sample was predominantly female (n=200, 62.3%). The year of 
diagnosis ranged between 1973 and 2010. The majority of patients had a sedentary 
lifestyle: 174 patients (56.3%) did not exercise. In addition, a small amount of 
patients in this study population smoked (n=39; 12.5%) and used alcohol (n=33; 
10.6%).  
 
A large proportion of patients had concomitant Hypertension (n=286; 89.1%) and 
dyslipidaemia (n=264; 82.2%). More than half of the patients were classified as 
obese according to the WHO classification. A staggering, 91.2% (n=266) fulfilled 
the criteria for diagnosis of the metabolic syndrome. 
 
The following insulin regimens were used: Protophane only 11.2% (n=36), bi-daily 
Actraphane 73.2% (n=235), combination of Protophane and Actrapid 4.6% (n=47) 
and Actraphane/Actrapid combination 0.9% (n=3).  Analysis of the small number of 
patients in the Actraphane/Actrapid group, would not have revealed any significant 
results. This group was thus excluded from further analysis.  
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Metformin was used in 72.5% (n=228) of patients. Of note, the majority of patients 
were being treated with statins, aspirin and Angiotensin Converting Enzyme 
Inhibitors. A complete list of medications used can be found in table 2. 
 
Achievement of targets: 
Table 3 shows detailed analysis of each variable. Figure 1 and table 4 depicts 
percentage of patients achieving targets. 
 
Anthropometric measurements 
The mean average Systolic BP was 144 mmHg (sd 20; range 98-245 mmHg) and the 
mean average Diastolic BP was 81 mmHg (sd 20; range 98-245 mmHg). Only 72 
patients achieved the target BP of <140/90mmHg (25.1%; 95% CI=20.2-30.5). Target 
waist circumference was taken to be <80cm for females and ≤ 94cm for males. Mean 
waist circumference was found to be 109cm for females (sd 16 cm; range 72-160 cm) 
and 106cm for male (sd 15 cm; range 55-157 cm) and only 32 patients (11%; 955 CI 
7.9-15.1) had ideal waist circumference .  
 
Blood results 
Target HbA1c used for the purpose of this study was 7% or lower which is the 
SEMDSA recommended guideline for the majority of patients.(12) The reason for this 
was that though the SEMDSA guidelines for target HbA1c differs according to age, 
prevalence of cardiovascular risk factors, hypoglycaemic unawareness and general 
overall prognosis; no clear outline of age range and prognosis is given.(12) 
Additionally, data collected during this study did not include incidence of 
hypoglycaemic events, patient’s awareness of hypoglycaemia and presence of 
target organ damage. In addition, factors affecting the HbA1c analysis (example 
anaemia) was not assessed. The mean HbA1c in this study population was 9.5% 
(SD 2.4; range 3.9-16.2%). Only 49 (15.3%; 95% CI 11.5-19.7) achieved the target 
HbA1c of 7% or less. Figure 2 depicts the range of HbA1c. 
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Data has demonstrated that the number of daily insulin injections is inversely 
proportional to compliance.(13) Thus greater injection numbers equal higher HbA1c 
levels. Table 5 illustrates the relationship between insulin regimen and HbA1c. There 
was no significant association between patients with HbA1c at target and insulin 
regimen used (p=0.85). There was however, a higher mean HbA1c level amongst 
patients on basal bolus than those using other regimens, even when controlling for 
co-morbidities.  
 
Analysis of lipograms revealed unequally distributed data with: Median total 
cholesterol of 4.4mmol/l (IQR 3.6-5.2), median triglyceride level of 1.6mmol/l (IQR 
1.1-2.2), median LDL-cholesterol of 2.4mmol/l (IQR 1.9-3.0) and median HDL-
cholesterol level of 1.0mmol/l (IQR 0.9-1.2) for males and 1.1mmol/l (IQR 0.9-1.4) for 
females. Target LDL-cholesterol was taken to be <1.8mmol as recommended by the 
current SEMDSA guidelines.(10, 12) Only 71 patients (22.6%; 95% CI 18.1-27.6%) had 
LDL-cholesterol levels below the target. 61.3% (n=192) and 46.6% (n=146) of 
patients had low HDL-cholesterol and high triglyceride levels respectively. The only 
statin available at the time was Simvastatin. The relationship to dose was not 
assessed. 
 
DISCUSSION 
The rapid rise in prevalence of DM in the last few decades has generated concern 
globally. (2,7) The socio-economic concerns stemming from this disease and its 
complications are extensive, affecting all levels of society.(5,14) As a result, healthcare 
organisations worldwide have produced evidenced based guidelines to assist 
clinicians with the screening, diagnosis and management of DM.(10, 11, 14)  
 
The establishment of specialised Diabetic clinics is an attempt to improve access to 
healthcare and a continuous supply of medication for all individuals.(10) At hospital 
level, diabetic clinics are referral centres for the complicated and often difficult to treat 
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patients. Regular audits of these institutions allows management to assess systems 
and protocols and address areas of concern.(10) 
 
Audits of diabetic clinics, in South Africa and internationally reveal that even with 
evidenced based guidelines, only small numbers of patients are able to achieve set 
targets.(15, 16) South African studies have revealed glycaemic target achievement in 
≤30% of patients in both the public and private health care sectors. Achievement of 
target BP and LDL-cholesterol was only slightly better.(18–21)  Moreover, Pinchevsky 
et al. demonstrated a decline in percentage of patients achieving targets between the 
years 2009 and 2013 in their audit of the Charlotte Maxeke Johannesburg Academic 
Hospital diabetic clinic.(21) International studies reveal only slightly better results with 
the greatest level of target achievement in resource-rich developed countries.(21–25) 
 
Our cohort of 321 patients consisted mainly of black and coloured patients consistent 
with the South African demographic, the drainage area of the hospital and the 
individuals that reported using public health care facilities in the last South African 
Household Survey.(26) Female predominance is consistent with findings from Hilawe 
et.al and cohorts noted in other studies.(16,27) Similarly the mean age of 59.4 years is 
in keeping with other cohorts.(23–25) 
 
Rates of smoking in this study population was found to be lower than the reported 
South African national average.(28) Use of alcohol was also noted in only a small 
percentage of patients. Though these rates are low; considering the fact that both 
smoking and excessive alcohol use confer additional risk in terms of cardiovascular 
disease and other complications; it is imperative that patients who require assistance 
with cessation of these risk activities be identified and helped. 
 
The low numbers of patients with HIV/AIDS in this cohort is surprising, considering 
the high prevalence of HIV/AIDS in South Africa.(9) This is most likely due to a 
combination of underreporting by patients and under-screening by clinicians. Another 
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reason may be that these patients are not being referred to the Diabetic Clinic (due to 
limited capacity) and are being treated at either the MOPD Clinic or the HIV Clinic. 
The interactions between HIV/AIDS and NCD’s as well as their treatments have been 
well documented.(29–32) It is thus evident that further measures need to be taken 
within this diabetic clinic to ensure adequate screening and treatment for HIV/AIDS. 
 
The high prevalence of obesity, hypertension and dyslipidaemia is reflective of the 
global rise in the Metabolic Syndrome.(33) Considering the higher risk of 
cardiovascular disease and other complications in patients diagnosed with the 
metabolic syndrome, this is disquieting. Even more perturbing is the very low rates of 
achievement of HbA1c, BP and lipid targets set by the SEMDSA diabetes 
guidelines.(12)   
 
On cursory comparison with other studies, both national and international, it seems 
that the Helen Joseph Diabetes Clinic is achieving much lower rates than other 
clinics. This can be seen in the meta-analysis done by Pinchevsky et el. in 2015.(16) 
However, it must be noted that formal comparison with these studies cannot be done 
as all the sample populations and settings are heterogeneous to the one in this 
study. That is, the study populations in most similar studies comprise of either a mix 
of patients with both T1DM and T2DM or all patients with T2DM, regardless of 
treatment regimen. Additionally, the majority of studies looking at similar outcomes 
have been carried out in primary health care settings as opposed to specialised 
diabetic clinics like the one at Helen Joseph Hospital. Still, the trend in many of these 
studies is lower levels of target achievement in individuals with T2DM who are on 
insulin based therapy, as opposed to those receiving oral hypoglycaemic agents.(16) 
 
The reasons for low rates of target achievement are multifactorial and some have 
been noted in large multicentre studies such as the Diabetes Attitudes, Wishes, and 
Needs (DAWN) Program conducted across 11 countries in America, Europe, Asia 
and Australia.(34) These reasons encompass patient, care-giver and system factors 
that influence outcomes. The most pertinent factors will be discussed.   
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Education is the cornerstone of any good management plan. Education of both 
patients and doctors have been proven to improve outcomes in diabetic patients.(35–
37) Education with regards to illness and treatment, amongst South African patients in 
the public sector has been demonstrated to be poor.(38) The implementation of 
structured education programmes with a focus on diabetes self-management is 
encouraged. Additionally, diabetic educators and physicians require continuous 
training in order to offer the best possible patient care. 
 
With the high rates of obesity noted in this study it is imperative that intervention be 
directed toward maintaining an adequate weight loss program as this can has been 
demonstrated to have many advantages including better control and even reversal of 
concomitant diseases and prevention of complications.(39,40) Weight management can 
also significantly impact psychosocial well- being and quality of life.(41)  
 
At the Helen Joseph diabetic clinic, patients have access to a dietician and receive 
group education on diet and exercise. Exercise is recorded in clinic notes in a yes/no 
manner and <50% of patients were recorded as exercising. Compliance to diet was 
not assessed in this audit. There is thus a clear need to further analyse patients 
understanding, perceptions and compliance to diet and exercise regimens.  Other 
barriers toward lifestyle changes that have been noted are the perceived high costs 
of healthy food(42) and risk of exercise associated complications (example: 
hypoglycaemia). SEMDSA recommends individualised medical nutrition therapy and 
exercise programmes.(12) Collaboration with community based diet and exercise 
programmes could be a feasible and useful option. Consideration of appropriate 
patients for medical management of weight loss and bariatric surgery and ensuring 
access to these treatments in the public sector would also assist with improving 
outcomes. 
 
Open and easy channels of communication and appropriate glucose monitoring 
ensures that adequate and timely changes to treatment, diet and exercise 
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programmes can be implemented.(42, 43) Thus target levels can be achieved quickly 
and sustained for long periods. Glucose monitoring was not assessed in this study 
and may be an area that needs further evaluation in future. As communication in our 
technology driven age becomes easier, the implementation of online forums and 
support groups may enhance treatment.  
 
Another area that poses a large obstacle to the ability of patients in the public sector 
achieving targets is the lack of access to appropriate medications, as well as the lack 
of consistency in obtaining medications. As compared to the 2012 Guidelines, the 
latest 2017 SEMDSA guidelines advocates the use of Glicazide as the only 
sulphonylurea, however it is not available in the state sector. (12) Other drugs used as 
first line oral additions to Metformin are also unavailable. The 2017 Guidelines also 
advocates the use of Indapamide as the diuretic of choice for the treatment of 
hypertension.(12) Again, this medication is not available in the public sector. 
 
Other notable reasons for poor target achieving that have been widely recognised is 
patient and doctor inertia to increase current treatments despite poor control and 
fears surrounding starting insulin therapy.(45) Psychosocial factors also contribute 
considerably to patient outcomes. Patients’ perceived burden of illness, fears of 
complications and treatment, as well as depression affect health related quality of life 
and adherence to treatment and follow-ups. These factors have a major impact on 
control of disease and outcomes.(39, 40)  Early recognition of anxiety and depression 
as well as ensuring adequate access to support groups and counselling is essential. 
 
Further analysis of the patients at the Helen Joseph Hospital Diabetic clinic is 
imperative in order to assess which of these barriers is prevalent and where 
intervention is most needed. In the interim, some universal steps to intensify 
treatment, monitoring and education can be undertaken to ensure that greater targets 
can be achieved. A multi-disciplinary approach involving the patient, the patients 
support network and the health care team together with individualisation of treatment 
will ensure better treatment outcomes and quality of life. 
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The Diabetic Clinic at Helen Joseph Hospital is a referral clinic for the MOPD, the 
Polyclinic (a primary health care clinic based at the hospital), as well as the regional 
and district level clinics. Due to its nature as being a tertiary referral centre, most 
patients referred are either poorly controlled or have significant complications. Once 
patients have achieved and maintained a good level of control, they are often 
stepped down back to their respective referral clinics. These factors could also play a 
major role into understanding why a higher level of HbA1c was found in this study 
group of patients.  
 
CONCLUSION 
Despite adequate protocols and access to tertiary medical care, only a very small 
percentage of patients at the diabetic clinic are achieving proposed targets. Potential 
barriers identified include: lack of education, inertia in increasing medication and lack 
of access to newer agents to treat diabetes. Prospective evaluation of these and other 
factors needs to be conducted in order to advise on appropriate cost effective resource 
allocation for our ever increasing diabetic population. 
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TABLES: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
BMI = Body Mass Index. Metabolic syndrome  as per International Harmonised Criteria. 
 
 
 
Table 1: Demographic Data 
Variable Category Number % 
  N=321   
Gender 
Female 200 62.3 
Male 121 37.7 
Ethnicity 
Black 143 44.6 
Coloured 109 34.0 
Indian 44 13.7 
White 25 7.8 
Comorbidities 
Hypertension 286 89.1 
Dyslipidaemia 264 82.2 
HIV 15 4.7 
Thyroid disease 14 4.4 
None 8 2.5 
Exercise 
Yes 174 56.3 
No 135 43.7 
Unknown 12 3.7 
Smoking 
Yes 39 12.5 
Never 220 70.7 
Ex-smoker 52 16.7 
Unknown 10 3.1 
Alcohol use 
Yes 33 10.6 
No 277 89.4 
Unknown 11 3.4 
Medication 
Actraphane 235 73.2 
Protophane+Actrapid 47 14.6 
Protophane 36 11.2 
Actraphane+Actrapid 3 0.9 
BMI (kg/m2) 
<30 127 42.3 
30-34.9 84 28.0 
35-39.9 56 18.7 
>=40 33 11.0 
Unknown 21 6.5 
Metabolic syndrome 
>=3 criteria 266 90.2 
0-2 criteria 29 9.8 
Unknown 26 8.1 
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Table 2: Medications Used 
Medication 
Number of 
Patients  
Percentage of 
Patients 
Statin (Simvastatin) 294 91.6 
ASA  280 87.2 
ACE-I/ARB  258 80.4 
Metformin  228 71.0 
Diuretic  216 67.3 
CCB  191 59.5 
Β-blocker  82 25.5 
Tryptanol  75 23.4 
PPI  75 23.4 
Alpha blocker  50 15.6 
ARVs  28 8.7 
Tegretol  21 6.5 
Fibrate  7 2.2 
Allopurinol  7 2.2 
Colchicine  3 0.9 
Thyroxine  3 0.9 
Other  15 4.7 
 
 
 
BMI = Body Mass Index; WC = Waist Circumference; SBP = Systolic Blood Pressure; DBP = Diastolic Blood Pressure, HbA1c = 
Glycated Haemoglobin; HDL = High Density Lipoprotein; LDL = Low Density Lipoprotein 
 
 
Table 3: Analysis of Variables 
Variable N Mean 
Std 
Dev Median 
Interquartile 
range Minimum Maximum 
Age (y) 321 59.4 9.9 60.0 53.0 66.0 30.0 88.0 
BMI (kg/m2) 300 32.1 8.8 3103 26.6 36.0 16.8 103.8 
WC (male) (cm) 111 106 16 105 94 114 72 160 
WC (female) (cm) 181 109 15 108 101 117 55 157 
SBP (average) (mmHg) 287 144 20 143 129 157 98 245 
DBP (average) (mmHg) 287 81 11 82 73 88 53 122 
HbA1c (%) 321 9.5 2.4 9.4 7.8 11.1 3.9 16.2 
Total cholesterol (mmol/l) 315 4.46 1,09 4.35 3.62 5.16 2.05 9.28 
Triglycerides (mmol/l) 313 1.89 1,27 1.61 1.09 2.20 0.43 11.70 
HDL cholesterol (male) 
(mmol/l) 116 1.07 0,29 1.03 0.90 1.17 0.57 2.77 
HDL cholesterol (female) 
(mmol/l) 197 1.16 0,34 1.10 0.91 1.38 0.60 2.52 
LDL cholesterol (mmol/l) 301 2.49 0,91 2.36 1.89 3.01 0.29 6.03 
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BMI = Body Mass Index;; SBP = Systolic Blood Pressure; DBP = Diastolic Blood Pressure, BP = Blood Pressure; HbA1c = 
Glycated Haemoglobin; HDL = High Density Lipoprotein; LDL = Low Density Lipoprotein 
 
 
 
HbA1c = Glycated haemoglobin 
 
 
 
 
 
 
 
 
 
 
Table 4: Patients who meet targets 
Measurement n % 
95% CI 
(%) 
SBP (n=287) 131 45,6 40,0 51,6 
DBP(n=287) 131 45,6 40,0 51,6 
BP (<=140/80 mm Hg) (n=287) 72 25,1 20,2 30,5 
Waist circumference (n=292) 32 11,0 7,9 15,1 
BMI (n=300) 127 42,3 36,7 48,1 
HbA1c (n=321) 49 15,3 11,5 19,7 
Total cholesterol (n=315) 169 53,7 48,0 59,3 
Triglycerides (n=313) 167 53,4 47,7 59,0 
HDL cholesterol (n=313) 135 43,1 37,6 48,8 
LDL cholesterol (n=314) 71 22,6 18,1 27,6 
Table 5: Relationship between Insulin Regimen and HbA1c 
Insulin Type n % 
Mean 
STD 
Dev Minimum Maximum 
HbA1c 
< 7% 
HbA1c 
≥  7% 
Actraphane 235 73.2 9.4 2.4 3.9 14.8 15.7 84.3 
Protophane+Actrapid 
(basal bolus) 
47 14.6 
10.4 2.5 4.7 16.2 12.8 87.2 
Protophane 36 11.2 9.4 2.4 5.7 15.0 16.7 83.3 
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FIGURES: 
Figure 1: Percentage of patients who met targets 
 
SBP = Systolic Blood Pressure; DBP = Diastolic Blood Pressure, HDL = High Density Lipoprotein; LDL = Low Density 
Lipoprotein 
 
 
 
Figure 2: HbA1c Range 
 
 
 
72 
 
APPENDICES 
                      
 Study No:         Appendix A 
           
                      
  1. Demographics:           
             
  Race: Black White Indian Coloured Other      
             
  Sex: Male Female         
             
  Age:             
                      
             
  2. History:           
             
  Year of diagnosis             
             
  Year Insulin started:             
                      
             
 3.Treatment:           
   Dose     Dose   
  Actraphane        Protophane       
           
  Actrapid        Metformin       
             
  Diuretic        CCB       
             
  ACE/ARB        
Beta-
blocker 
      
             
  Alpha-blocker        Statin        
           
  Fibrate        Tryptanol       
             
  Allopurinol        Tegretol       
             
  Colchcine        Aspirin       
             
  Other                  
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 Study No:        Appendix A 
           
                      
  4. Clinical Parameters:           
             
  Height     
cm 
      
    
  
 
     
  Weight    
kg 
      
    
  
 
      
  Systolic Blood Pressure    
mm Hg 
      
    
  
 
      
  Diastolic Blood Pressure    
mm Hg 
      
    
  
 
      
  Abdominal Circumference    
cm 
      
                      
             
  5. Laboratory findings:           
             
  
Glycated Haemaglobin 
(HbA1c)   %       
             
  Total cholesterol   mmol/l       
             
  Triglyceride   mmol/l       
             
  HDL cholesterol   mmol/l       
             
  LDL cholesterol   mmol/l       
             
  TSH   mmol/l       
                      
 
 
